Novo Nordisk A/S ADR buy UBS Group AG
Start price
08.01.25
/
50%
€83.20
Target price
08.01.26
-
Performance (%)
-27.16%
Price
09.07.25
€59.50
Summary
This prediction is currently active. The price of Novo Nordisk A/S ADR has decreased since the start of the prediction. Compared to the start price this results in a performance of -27.16%. Dividends of €1.10 are taken into consideration when calculating the performance. This prediction currently runs until 08.01.26. The prediction end date can be changed by UBS_Group_AG at any time. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Novo Nordisk A/S ADR | 0.677% | 0.677% |
| iShares Core DAX® | 3.459% | 1.746% |
| iShares Nasdaq 100 | 1.711% | 2.027% |
| iShares Nikkei 225® | -0.340% | 0.817% |
| iShares S&P 500 | 1.295% | 1.490% |
Comments by UBS_Group_AG for this prediction
In the thread Novo Nordisk A/S ADR diskutieren
Novo Nordisk A/S (NYSE: NVO) was upgraded by analysts at UBS Group AG from a "sell" rating to a "buy" rating.
Ratings data for NVO provided by MarketBeat